Who are Ad26.COV2.S vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MVC-COV1901(6 Months), Pfizer-COVID-19 Vaccine, BNT162b7 Bivalent (Original/OMI BA.4/BA.5), BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b5 Bivalent (WT/OMI BA.2), Casirivimab and Imdevimab Drug Combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ad26-cov2-s-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ad26.COV2.S vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ad26.COV2.S vaccine (Ad26.COV2.S vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: viral vector vaccine. Area: Immunology / Infectious Disease.

marketed viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Ad26.COV2.S vaccine (Ad26.COV2.S vaccine) — University Medical Center Groningen. Ad26.COV2.S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ad26.COV2.S vaccine TARGET	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
MVC-COV1901(6 Months)	MVC-COV1901(6 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein (S-2P)
Pfizer-COVID-19 Vaccine	Pfizer-COVID-19 Vaccine	National Heart, Lung, and Blood Institute (NHLBI)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
BNT162b7 Bivalent (Original/OMI BA.4/BA.5)	bnt162b7-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b6 Bivalent (Original/OMI BA.4/BA.5)	bnt162b6-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b5 Bivalent (WT/OMI BA.2)	bnt162b5-bivalent-wt-omi-ba-2	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (viral vector vaccine class)

Jiangsu Province Centers for Disease Control and Prevention · 3 drugs in this class
University Medical Center Groningen · 1 drug in this class
Vinbiocare Biotechnology Joint Stock Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ad26.COV2.S vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ad26-cov2-s-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab